PTO/SB/08b (07-09) Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for fo	rm 1449B/PT0	)		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/598,533	
				Filing Date	09-01-06	
				First Named Inventor	Yoshinobu YAMAZAKI	
				Art Unit	1614	
				Examiner Name	BLAKELY III, NELSON CLARENCE	
Sheet	1	of	1	Attorney Docket Number	Q96716	

NON PATENT LITERATURE DOCUMENTS					
Examiner initial *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2		
	1	ABRAMS Paul, et al., "Tamsulosin: Efficacy and Safety in Patients With Neurogenic Lower Urinary Tract Dysfunction Due to Suprasacral Spinal Cord Injury", Journal of Urology, Vol. 170, pp. 1242-1251, 2003.			
	2	SHIBATA, Katsashi, et al., "KMD-3213, a Novel, Potent, a1a-Adrenoceptor-Selective Antagonist: Characterization Using Recombinant Human a1-Adrenoceptors and Native Tissues.			
			E		
			E		
			F		

Examiner	Date
Signature	Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

consource, notices copy of this form with next communications to applicant.

1, Applicants unique failuration designation mathic cylorismity 2, Applicants in topic as check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 157 and 158. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 US. CF. 22 and 37 CFR 1.14 the loodeding is estimated to their 26 burst to commind to their 26 burst to commind to their 26 burst to commind on the amount of films you require programs, and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any communition the amount of films you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheff Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.